Last reviewed · How we verify
HRS-8080 Tablets — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
HRS-8080 Tablets (HRS-8080 Tablets) — Shandong Suncadia Medicine Co., Ltd.. HRS-8080 is an investigational small molecule with unknown mechanism of action in Phase 3 development.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HRS-8080 Tablets TARGET | HRS-8080 Tablets | Shandong Suncadia Medicine Co., Ltd. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HRS-8080 Tablets CI watch — RSS
- HRS-8080 Tablets CI watch — Atom
- HRS-8080 Tablets CI watch — JSON
- HRS-8080 Tablets alone — RSS
Cite this brief
Drug Landscape (2026). HRS-8080 Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/hrs-8080-tablets. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing